Elevated gamma-glutamyl transferase levels are associated with stroke recurrence after acute ischemic stroke or transient ischemic attack

Siqi Li1,2 | Anxin Wang1,2 | Xue Tian1,2 | Yingting Zuo1,2 | Xia Meng1,2 | Yumei Zhang1,2,3

Abstract

Aims: Gamma-glutamyl transferase (GGT) is considered a marker of oxidative stress in vivo. In this study, we aimed to examine the association of serum GGT levels with 3-month and 1-year stroke recurrence in patients with acute ischemic stroke or transient ischemic attack (TIA).

Methods: We conducted a large and multicenter cohort study. Participants with ischemic stroke or TIA who had a baseline GGT measurement were enrolled in the China National Stroke Registry-3 study from August 2015 to March 2018. They were divided into four groups according to sex-specific quartiles of GGT levels. The effect of GGT on stroke recurrence and other vascular events was examined during the 1-year follow-up period. Multivariate Cox regression models were performed to evaluate the association. Discrimination tests were used to examine the degree to which incorporating GGT into the conventional model predicted stroke adverse outcomes.

Results: A total of 12,504 patients were enrolled. At both the 3-month and 1-year follow-ups, patients in the highest quartile group of GGT levels exhibited a higher risk of stroke recurrence [HR 1.32 (95% CI 1.07–1.63), HR 1.34 (95% CI 1.13–1.60)], ischemic stroke [HR 1.37 (95% CI 1.10–1.71), HR 1.37 (95% CI 1.14–1.64)], and combined vascular events [HR 1.34 (95% CI 1.09–1.65), HR 1.34 (95% CI 1.13–1.59)] than those in the lowest quartile group. Moreover, the Kaplan–Meier curves revealed that the incidence rates of stroke adverse outcomes were quite different in the four groups. The highest quartile group showed the highest cumulative incidence, while the lowest quartile group showed the lowest cumulative incidence. After applying discrimination tests, adding GGT into the conventional model resulted in slight improvements in predicting stroke adverse outcomes (NRI: 10%–14%).

Conclusion: This study demonstrated that elevated GGT levels were positively associated with an increased risk of stroke adverse outcomes, namely, recurrence, ischemic stroke, and combined vascular events.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.
INTRODUCTION

Stroke is the leading cause of death and disability worldwide. Previous studies have shown that nearly 20% of stroke patients will have recurrence of stroke. Approximately 50% of recurrent strokes occur within a few days to a few weeks after ischemic cerebrovascular disease. In addition, recurrent stroke may lead to the deterioration of functional outcomes, decreased quality of life, and even increased mortality. Therefore, it is necessary to predict the risk of recurrence and new vascular events in stroke patients in a timely manner.

Gamma-glutamyl transferase (GGT) is a recognized serum marker of alcoholic liver disease. It has been reported to be associated with the identification of a variety of diseases. Multiple previous studies reported an association between GGT activity and cardiovascular disease events (CVDs) in healthy populations. Researchers have observed that people with higher GGT levels were more likely to develop stroke after a period of follow-up than those with lower GGT levels. In addition, some studies have further focused on stroke patients to investigate the relationship between GGT levels and stroke. A study showed that GGT activity was more strongly associated with cardioembolic stroke among ischemic stroke patients, which was largely due to the presence of atrial fibrillation. Moreover, researchers further explored the association between GGT levels and adverse clinical outcomes of CVDs in stroke patients. Results showed that elevated serum GGT levels were associated with all-cause or cardiovascular disease mortality after stroke and might be independent of alcohol consumption. However, the relationship between GGT activity and other stroke adverse outcomes, namely, recurrence, ischemic stroke, and combined vascular events, remains to be further elucidated. Interestingly, a previous study found that the significant association between GGT activity and stroke was no longer significant after adjustment for multiple factors, which meant that GGT activity might be less likely to predict the severity of cardio-cerebrovascular diseases. Thus, the objectives of this study were to examine the association of serum biomarker GGT levels with stroke adverse outcomes, namely, recurrence, ischemic stroke, and combined vascular events, and to evaluate whether GGT levels can predict the risk of stroke adverse outcomes at the 3-month and 1-year follow-ups.

METHODS

2.1 Study population

The China National Stroke Registry-3 (CNSR-3) study is a large multicenter study that includes approximately 201 hospitals and national registries in China and recruited consecutive patients from August 2015 to March 2018. We identified 15,166 participants who were selected from the CNSR-3 study. The inclusion criteria for participants in this study were as follows: (i) patients diagnosed with acute ischemic stroke (AIS) or transient ischemic attack (TIA); (ii) patients hospitalized within 7 days from symptom onset; and (iii) patients who were older than 18 years. Among these patients, the following were further excluded: 2291 patients who lacked serum GGT data at baseline and 371 patients who were lost to follow-up. Ultimately, the total number of eligible participants in the present study was 12,504.

The present study was performed in accordance with the guidelines described by the Helsinki Declaration and was approved by the Ethics Committees of Beijing Tiantan Hospital (No. KY2015-001-01). All participants signed a written informed consent form prior to their inclusion in the study.

2.2 Data collection

The baseline data of the enrolled participants were collected following the standard data collection protocol developed by the steering committee. The protocol and the statistical analysis plan have been published in a previous study.

The information from all participants was collected by comprehensive assessments on admission and detailed medical records, including baseline characteristics (age, sex, body mass index, alcohol consumption, smoking status, etc.), medical histories (stroke or TIA, hypertension, cardiovascular disease, dyslipidemia, diabetes mellitus, peripheral vascular disease) and physical examination results (blood pressure, the modified Rankin Scale (mRS) score, the National Institutes of Health Stroke Scale (NIHSS) score). All imaging data were collected in DICOM format on disks and analyzed by two professional neurologists. Moreover, exposure to various medications during hospitalization (antiplatelet aggregation therapy, anticoagulation treatment, antihypertensive treatment) was assessed. In addition, serum GGT, fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels from fasting blood samples were collected carefully and with high quality within 24 h of admission to address potential sources of bias. All blood samples were stored in EDTA anticoagulant collection tubes and serum separation tubes in a −80°C refrigerator.

2.3 Outcome evaluation

The primary clinical outcome was stroke recurrence (defined as a new focal neurological impairment due to acute stroke events,
including new ischemic stroke and hemorrhagic stroke, which was confirmed by neuroimaging). The secondary clinical outcomes were ischemic stroke and combined vascular events (nonfatal stroke, nonfatal myocardial infarction, cardiovascular death). The outcomes mentioned above were observed at 3 months and 1 year after stroke onset. According to the World Health Organization criteria, the diagnostic criteria for stroke rely on symptoms, physical signs, scale evaluations, and neuroimaging (magnetic resonance or brain computed tomography).25,26

2.4 | Statistical analysis

The data were tested for normal distribution using the Kolmogorov–Smirnov test. Continuous variables conforming to a normal distribution are presented as the means ± standard deviations (SDs) and were compared using ANOVA. Continuous variables that did not exhibit a normal distribution are presented as medians with interquartile ranges (IQRs) and were compared using the Kruskal–Wallis U test. Categorical variables are expressed as numbers (proportions) and were compared using the χ²-test or Fisher’s exact test.

First, patients participating in this study were divided into four groups according to sex- specific quartiles of GGT, which was assessed on admission. Then, the association of GGT levels with stroke recurrence, ischemic stroke, and combined vascular events was estimated by using a multivariate Cox regression model. In addition, hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated after adjusting for potential confounding factors. The first model was adjusted for age and sex. In the second model, body mass index (BMI), smoking status, alcohol consumption and medical histories were added. In the third model, systolic blood pressure (SBP), diastolic blood pressure (DBP), the NIHSS score at admission, the mRS score, the TOAST classification (including five subtypes of ischemic stroke: large-artery atherosclerosis, cardioembolism, small-vessel occlusion, other determined etiologies, and undetermined causes),27 medications received during hospitalization (including antiplatelet therapy, anticoagulation treatment, antihypertensive treatment, and lipid-lowering drugs), and laboratory tests were further added. In addition, restricted cubic spline analysis was used to address the association. Furthermore, we used Kaplan–Meier analysis to address survival plots of time to stroke recurrence and other vascular events during the 1-year follow-up period, and each group was compared by the log-rank test. Discrimination tests (C statistics and net reclassification improvement [NRI]) were used to evaluate whether GGT activity improve risk prediction for stroke adverse outcomes. We established the conventional model using various parameters, including age, sex, body mass index, smoking status, NIHSS score at admission, and a medical history of stroke, hypertension, dyslipidemia, diabetes mellitus and cardiovascular diseases.16,20 Then, the interaction of age (<60 or ≥60 years), sex, alcohol consumption and TOAST classification was examined by subgroup analysis, adjusted in the third model. In addition, we further performed sensitivity analyses to validate the robustness of the results. First, the Cox proportional hazard regression model, adjusted for the factors in Model 3 plus liver diseases (including liver dysfunction and cirrhosis), was applied. Second, the restricted analysis was performed by excluding individuals with liver diseases (including liver dysfunction and cirrhosis) at baseline. Third, the competing risk model was applied to assess the associations between GGT levels and stroke adverse outcomes, with non-CVD death being regarded as a competing risk event. In this study, p-values < 0.05 were considered to be statistically significant and were two-sided.

All statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc.).

3 | RESULTS

3.1 | Baseline characteristics

As shown in Figure 1, among the 15,166 patients in the CNSR-3 study, 12,504 participants who had baseline GGT measurements and completed the 1-year follow-up were enrolled, and their
baseline characteristics are shown in Table 1 and Table S1. The participants were categorized into four groups according to sex-specific quartiles of GGT at baseline (men: <19 IU/L, 19–27 IU/L, 27–43 IU/L, ≥43 IU/L; women: <14 IU/L, 14–20 IU/L, 20–29 IU/L, ≥29 IU/L). We found that patients with higher GGT levels were predominantly male and younger overall and were more likely to be obese, current smokers and drinkers and have higher blood pressure and FBG, TC, TG, ALT, and AST levels.

3.2 | Clinical outcomes

During the 1-year follow-up period, among the eligible participants, 787 (6.29%) patients had stroke recurrence, 736 (5.89%) had ischemic stroke, and 815 (6.52%) had combined vascular events within 3 months. At the 1-year follow-up, 1235 (9.88%), 1134 (9.07%), and 1307 (10.45%) patients had recurrent stroke, ischemic stroke, and combined vascular events, respectively. The associations of GGT levels with stroke adverse outcomes are presented in Table 2. At the 3-month follow-up, compared with those in the lowest group, patients in the highest GGT level group showed 32%, 37%, and 34% increases in recurrent stroke [HR (95% CI): 1.32 (1.07–1.63)], ischemic stroke [HR (95% CI): 1.37 (1.10–1.71)], and combined vascular events [HR (95% CI): 1.34 (1.09–1.65)]. The association persisted, even after adjusting for the potential confounding factors mentioned above. Moreover, this positive association remained after the 1-year follow-up, and elevated GGT levels revealed adjusted hazard ratios of 1.34 (95% CI: 1.13–1.60), 1.37 (95% CI: 1.14–1.64), and 1.34 (95% CI: 1.13–1.59) for stroke recurrence, ischemic stroke, and combined vascular events, respectively. Notably, the restricted cubic spline analysis also demonstrated an increase in the risk of stroke adverse outcomes with increasing GGT levels (Figure 2).

In addition, according to serum GGT levels, the Kaplan–Meier curves showed the time to event for stroke recurrence, ischemic stroke, and combined vascular events at the 3-month and 1-year follow-ups (Figure 3). The incidence rates of stroke recurrence, ischemic stroke, and combined vascular events were quite different at all times in these 4 groups, especially between Q1 and Q4. The top of the fourth quartile showed the highest cumulative incidence of these outcomes, while the bottom of the fourth quartile showed the lowest cumulative incidence.

After applying discrimination tests, there was a slight improvement in predicting the risk of stroke adverse outcomes, namely, recurrence, ischemic stroke, and combined vascular events, when adding GGT activity into the conventional model (including age, sex, body mass index, smoking status, NIHSS score at admission, and a medical history of stroke, hypertension, dyslipidemia, diabetes mellitus, and cardiovascular diseases) [3 months: NRI 14.00% (p = 0.0002), NRI 14.00% (p = 0.0003), NRI 14.00% (p < 0.0001); 1 year: NRI 11.00% (p = 0.0005), NRI 11.00% (p = 0.0003), NRI 10.00% (p = 0.0012), respectively] (Table 3).

According to previous studies, some demographic and physiological factors might result in different effects of GGT activity on stroke adverse outcomes. Thus, we further conducted an interaction analysis in this study. After stratifying by age, sex, alcohol consumption, and TOAST type, the analysis showed no significant interaction between the variables and GGT activity and the occurrence of stroke adverse outcomes (Table S2). Notably, low- and high-GGT levels refer to the lowest quartile of 25% and the remaining quartiles of 75%, respectively.

In addition, the sensitivity analyses adjusted for the factors in Model 3 plus liver diseases (Table S3), excluding individuals with liver diseases at baseline (Table S4), and the competing risk model (Table S5), all generated similar findings to the primary analysis.

4 | DISCUSSION

This large cohort study revealed a positive association between baseline serum biomarker GGT levels and stroke adverse outcomes, namely, recurrence, ischemic stroke, and combined vascular events, regardless of the length of time after stroke. This significant relationship persisted even after adjusting for other vascular risk factors, such as age, sex, BMI, alcohol consumption, blood pressure, hypertension, dyslipidemia, diabetes mellitus, cardiovascular disease, TOAST type, medical histories, medications received during hospitalization, and laboratory tests. These trends remained when the models were subjected to multiple sensitivity analyses. Interestingly, adding GGT activity into the conventional model resulted in a 10–14% increase in predicting stroke adverse outcomes. Moreover, after using correlation analysis to further observe the association between GGT activity and stroke recurrence, ischemic stroke, and combined vascular events in different subgroups, we found that the effect of GGT activity on these adverse outcomes remained consistent.

As a common adverse outcome after stroke, stroke recurrence seriously affects the quality of life of patients, but few studies have examined the role of GGT in stroke recurrence. Several studies indicated that elevated GGT levels were associated with future stroke risk, but these were all community studies that focused on healthy populations. A study with a small sample size observed that a high-GGT level was related to all-cause mortality in stroke patients. However, the relationship between GGT activity and stroke recurrence was not explored.

The strength of this large, multicenter cohort study is that it demonstrated the association between GGT activity and stroke adverse outcomes, namely, recurrence, ischemic stroke, and combined vascular events, which has rarely been mentioned in previous studies. Due to the significant sex difference in GGT levels, we divided GGT into four levels based on sex, eliminating the interference of this factor in the study. We followed these participants for a long period of time and found that elevated GGT levels were always positively associated with the risk of stroke recurrence.
| Characteristic                                    | Total | GGT level | p Value |
|--------------------------------------------------|-------|-----------|---------|
| N, (%)                                           | 12,504| 3291      | 3098    | 3080 | 3035 | <0.0001 |
| Age, year, median (IQR)                          | 63.00 (54.00–70.00) | 65.00 (58.00–73.00) | 64.00 (56.00–71.00) | 61.00 (53.00–69.00) | 60.00 (52.00–68.00) | <0.0001 |
| Male, n (%)                                      | 8506 (68.03) | 2288 (69.52) | 2011 (64.91) | 2147 (69.71) | 2060 (67.87) | <0.0001 |
| BMI, kg/m², median (IQR)                         | 24.49 (22.60–26.50) | 23.88 (22.03–25.80) | 24.49 (22.60–26.56) | 24.77 (22.99–26.80) | 24.80 (22.99–27.03) | <0.0001 |
| BP, mmHg, median (IQR)                           |       |           |         |       |       |         |
| SBP                                              | 148.00 (135.00–163.00) | 146.50 (134.00–161.50) | 148.00 (134.50–163.50) | 149.00 (135.00–165.00) | 149.00 (135.00–165.00) | 0.0033 |
| DBP                                              | 86.00 (79.00–95.00) | 84.50 (77.50–92.50) | 85.00 (77.50–92.50) | 85.00 (79.00–94.00) | 87.00 (79.50–96.00) | <0.0001 |
| Current smoking, n (%)                           | 10,399 (83.17) | 2715 (82.50) | 2600 (83.93) | 2533 (82.24) | 2551 (84.05) | 0.1158 |
| Current drinking, n (%)                          | 5559 (44.46) | 1308 (39.74) | 1272 (41.06) | 1449 (47.05) | 1530 (50.41) | <0.0001 |
| Medical histories, n (%)                         |       |           |         |       |       |         |
| Stroke or TIA                                     | 2781 (22.24) | 787 (23.91) | 731 (23.60) | 674 (21.88) | 589 (19.41) | <0.0001 |
| Hypertension                                     | 7850 (62.78) | 1923 (58.43) | 1999 (64.53) | 1980 (64.29) | 1948 (64.18) | <0.0001 |
| Diabetes mellitus                                | 2924 (23.38) | 636 (19.33) | 792 (25.56) | 761 (24.71) | 735 (24.22) | <0.0001 |
| Dyslipidemia                                      | 980 (7.84) | 223 (6.72) | 239 (7.71) | 265 (8.60) | 255 (8.40) | 0.0218 |
| Cardiovascular disease                           | 1687 (13.49) | 390 (11.85) | 396 (12.78) | 409 (13.28) | 492 (16.21) | <0.0001 |
| Peripheral vascular disease                      | 88 (0.70) | 29 (0.88) | 24 (0.77) | 15 (0.49) | 20 (0.66) | 0.2766 |
| Liver dysfunction                                 | 65 (0.52) | 11 (0.33) | 8 (0.26) | 11 (0.36) | 35 (1.15) | <0.0001 |
| Cirrhosis                                        | 26 (0.21) | 5 (0.15) | 7 (0.23) | 5 (0.16) | 9 (0.30) | 0.5718 |
| Medications during hospitalization                |       |           |         |       |       |         |
| Antiplatelet therapy                             | 12,057 (97.12) | 3196 (97.83) | 2986 (97.26) | 2979 (97.26) | 2896 (96.05) | 0.0033 |
| Anticoagulation treatment                        | 1294 (10.42) | 281 (8.60) | 300 (9.77) | 356 (11.62) | 357 (11.84) | <0.0001 |
| Antihypertensive treatment                       | 5705 (45.95) | 1373 (42.03) | 1441 (46.94) | 1393 (45.48) | 1498 (49.68) | <0.0001 |
| Lipid-lowering drugs                              | 11,942 (96.19) | 3144 (96.22) | 2954 (96.22) | 2956 (96.51) | 2888 (95.79) | 0.5327 |
| TOAST type, n (%)                                |       |           |         |       |       |         |
| Large-artery atherosclerosis                      | 3170 (25.35) | 815 (24.76) | 798 (25.76) | 814 (26.43) | 743 (24.48) | <0.0001 |
| Cardioembolism                                   | 769 (6.15) | 162 (4.92) | 165 (5.33) | 188 (6.10) | 254 (8.37) | <0.0001 |
| Small-vessel occlusion                           | 2589 (20.71) | 748 (22.73) | 644 (20.79) | 609 (19.77) | 588 (19.37) | <0.0001 |
| Other determined etiology                        | 164 (1.31) | 61 (1.85) | 42 (1.36) | 27 (0.88) | 34 (1.12) | 0.2323 |
| Undetermined cause                               | 5812 (46.48) | 1505 (45.73) | 1449 (46.77) | 1442 (46.82) | 1416 (46.66) | <0.0001 |
| NIHSS at admission, median (IQR)                 | 3.00 (1.00–6.00) | 3.00 (1.00–6.00) | 3.00 (1.00–6.00) | 3.00 (1.00–6.00) | 3.00 (1.00–6.00) | 0.2036 |

(Continues)
TABLE 1 (Continued)

| Characteristic | Total | GGT level | Q1       | Q2       | Q3       | Q4       | p Value |
|----------------|-------|-----------|----------|----------|----------|----------|---------|
|                |       |           | 1623 (49.32) | 1585 (51.16) | 1573 (51.07) | 1509 (49.72) | 0.3426 |
| Prestroke mRS ≤1, n (%) | 6290 (50.30) |           | 1623 (49.32) | 1585 (51.16) | 1573 (51.07) | 1509 (49.72) |       |
| Laboratory tests, median (IQR) |       |           | 1623 (49.32) | 1585 (51.16) | 1573 (51.07) | 1509 (49.72) |       |
| Serum GGT, IU/L | 24.00 (17.00–38.87) |       | 14.00 (12.00–17.00) | 21.00 (19.00–24.00) | 31.00 (27.00–36.00) | 57.00 (46.00–81.00) | <0.0001 |
| FBG, mmol/L | 5.51 (4.90–6.85) |       | 14.00 (12.00–17.00) | 21.00 (19.00–24.00) | 31.00 (27.00–36.00) | 57.00 (46.00–81.00) | <0.0001 |
| TC, mmol/L | 3.97 (3.31–4.72) |       | 14.00 (12.00–17.00) | 21.00 (19.00–24.00) | 31.00 (27.00–36.00) | 57.00 (46.00–81.00) | <0.0001 |
| TG, mmol/L | 1.37 (1.03–1.88) |       | 14.00 (12.00–17.00) | 21.00 (19.00–24.00) | 31.00 (27.00–36.00) | 57.00 (46.00–81.00) | <0.0001 |
| ALT, IU/L | 18.00 (13.00–25.00) |       | 14.00 (12.00–17.00) | 21.00 (19.00–24.00) | 31.00 (27.00–36.00) | 57.00 (46.00–81.00) | <0.0001 |
| AST, IU/L | 19.00 (16.00–24.00) |       | 14.00 (12.00–17.00) | 21.00 (19.00–24.00) | 31.00 (27.00–36.00) | 57.00 (46.00–81.00) | <0.0001 |

Note: Variables are expressed as median (IQR) or percentages. GGT was expressed as sex-specific quartiles (male: Q1, <14 IU/L; Q2, 14–20 IU/L; Q3, 20–29 IU/L; Q4, ≥29 IU/L). Cardiovascular disease included coronary heart disease, atrial fibrillation, and heart failure. Medication use indicated treatment during hospitalization.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; GGT, gamma-glutamyl transferase; IQR, interquartile range; mRS, the modified Rankin Scale; NIHSS, the National Institutes of Health Stroke Scale; Q, quartile; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; TIA, transient ischemic attack.
Moreover, the main causes of stroke are atherosclerosis and cardiogenic embolism, and these findings suggested that serum GGT activity was significantly associated with mortality. Moreover, the main causes of stroke are atherosclerosis and cardiogenic embolism, and these findings suggested that serum GGT activity was significantly associated with CCD risk. On this basis, the current study further confirmed the role of GGT in stroke recurrence and other vascular events and enriched the application of GGT activity in disease diagnosis.

### TABLE 2 Associations between GGT levels and stroke adverse outcomes at the 3-month and 1-year follow-ups

| Outcomes                      | GGT quartiles | Q1   | Q2   | Q3   | Q4   | p for trend |
|-------------------------------|---------------|------|------|------|------|-------------|
| **3 months**                  |               |      |      |      |      |             |
| Stroke recurrence             |               |      |      |      |      |             |
| Case, n (%)                   | 185 (5.62)    | 192 (6.20) | 191 (6.20) | 219 (7.22) |      |             |
| Model 1<sup>a</sup>           | 1             | 1.12 (0.92–1.37) | 1.15 (0.94–1.41) | 1.36 (1.12–1.66) | 0.0027 |             |
| Model 2<sup>b</sup>           | 1             | 1.10 (0.89–1.34) | 1.12 (0.91–1.37) | 1.31 (1.08–1.60) | 0.0092 |             |
| Model 3<sup>c</sup>           | 1             | 1.07 (0.88–1.32) | 1.09 (0.89–1.34) | 1.32 (1.07–1.63) | 0.0165 |             |
| Ischemic stroke               |               |      |      |      |      |             |
| Case, n (%)                   | 171 (5.20)    | 183 (5.91) | 177 (5.75) | 205 (6.75) |      |             |
| Model 1                       | 1             | 1.15 (0.94–1.42) | 1.16 (0.94–1.43) | 1.38 (1.12–1.69) | 0.0037 |             |
| Model 2                       | 1             | 1.13 (0.91–1.39) | 1.12 (0.91–1.39) | 1.33 (1.08–1.63) | 0.0114 |             |
| Model 3                       | 1             | 1.11 (0.90–1.37) | 1.10 (0.89–1.36) | 1.37 (1.10–1.71) | 0.0099 |             |
| Combined vascular events      |               |      |      |      |      |             |
| Case, n (%)                   | 193 (5.86)    | 196 (6.33) | 195 (6.33) | 231 (7.61) |      |             |
| Model 1                       | 1             | 1.10 (0.90–1.34) | 1.14 (0.93–1.39) | 1.39 (1.15–1.69) | 0.0010 |             |
| Model 2                       | 1             | 1.08 (0.88–1.32) | 1.11 (0.90–1.35) | 1.35 (1.11–1.64) | 0.0033 |             |
| Model 3                       | 1             | 1.06 (0.86–1.29) | 1.07 (0.88–1.32) | 1.34 (1.09–1.65) | 0.0089 |             |
| **1 year**                    |               |      |      |      |      |             |
| Stroke recurrence             |               |      |      |      |      |             |
| Case, n (%)                   | 282 (8.57)    | 313 (10.10) | 305 (9.90) | 335 (11.04) |      |             |
| Model 1                       | 1             | 1.21 (1.03–1.42) | 1.22 (1.04–1.44) | 1.39 (1.18–1.63) | 0.0001 |             |
| Model 2                       | 1             | 1.19 (1.01–1.40) | 1.20 (1.02–1.41) | 1.36 (1.16–1.60) | 0.0004 |             |
| Model 3                       | 1             | 1.17 (1.00–1.38) | 1.17 (0.99–1.38) | 1.34 (1.13–1.60) | 0.0020 |             |
| Ischemic stroke               |               |      |      |      |      |             |
| Case, n (%)                   | 257 (7.81)    | 289 (9.33) | 280 (9.09) | 308 (10.15) |      |             |
| Model 1                       | 1             | 1.22 (1.03–1.45) | 1.23 (1.04–1.46) | 1.40 (1.18–1.65) | 0.0002 |             |
| Model 2                       | 1             | 1.20 (1.02–1.42) | 1.20 (1.01–1.43) | 1.37 (1.15–1.62) | 0.0006 |             |
| Model 3                       | 1             | 1.19 (1.00–1.41) | 1.18 (0.99–1.40) | 1.37 (1.14–1.64) | 0.0014 |             |
| Combined vascular events      |               |      |      |      |      |             |
| Case, n (%)                   | 297 (9.02)    | 332 (10.72) | 325 (10.55) | 353 (11.63) |      |             |
| Model 1                       | 1             | 1.23 (1.05–1.43) | 1.25 (1.06–1.46) | 1.40 (1.20–1.64) | <0.0001 |             |
| Model 2                       | 1             | 1.21 (1.03–1.41) | 1.22 (1.04–1.43) | 1.37 (1.17–1.60) | 0.0002 |             |
| Model 3                       | 1             | 1.18 (1.01–1.39) | 1.19 (1.01–1.40) | 1.34 (1.13–1.59) | 0.0012 |             |

Note: HRs with 95% CIs were expressed by using multivariate Cox regression models. The HR of quartile 1 was set as the reference. GGT was expressed as sex-specific quartiles (men: Q1, <19 IU/L; Q2, 19–27 IU/L; Q3, 27–43 IU/L; Q4, ≥43 IU/L; women: Q1, <14 IU/L; Q2, 14–20 IU/L; Q3, 20–29 IU/L; Q4, ≥29 IU/L). Combined vascular events (stroke recurrence, myocardial infarction, and vascular death).

Abbreviations: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio; mRS, the modified Rankin Scale; NIHSS, the National Institutes of Health Stroke Scale; Q, quartile; SBP, systolic blood pressure.

<sup>a</sup>Model 1 was adjusted for age and sex.

<sup>b</sup>Model 2 was adjusted for the factors in model 1 plus BMI, smoking, alcohol consumption, and medical histories.

<sup>c</sup>Model 3 was adjusted for the factors in model 2 plus SBP, DBP, NIHSS score at admission, prestroke mRS score, TOAST types (including large-artery atherosclerosis, cardioembolism, small-vessel occlusion, other determined etiology and undetermined cause), medications during hospitalization (including antiplatelet therapy, anticoagulation treatment, antihypertensive treatment, lipid-lowering drugs), and laboratory tests (fasting blood glucose, total cholesterol, triglycerides, alanine aminotransferase, aspartate aminotransferase levels).
This study also had some limitations. First, since only patients with minor stroke (a low NIHSS score) and TIA were included in this study, these findings need validation in other cohorts. Second, for the interesting results of this study to be of greater breadth and relevance, further studies with longer follow-ups should be considered. Third, because of missing data for some variables of interest, the potential
TABLE 3: Reclassification and disclination statistics for stroke adverse outcomes when adding to GGT levels

| Clinical outcomes          | Model                  | C-statistic Estimate (95% CI) | p Value | NRI Estimate (95% CI) | p Value |
|----------------------------|------------------------|-------------------------------|---------|-----------------------|---------|
| 3months                    |                        |                               |         |                       |         |
| Stroke recurrence          | Conventional model     | 0.64 (0.62–0.66)              | 0.12    | Ref.                  | 0.0002  |
|                            | Conventional model +GFT| 0.65 (0.62–0.67)              | 0.11    | Ref.                  | 0.0003  |
| Ischemic stroke            | Conventional model     | 0.64 (0.62–0.66)              | 0.11    | Ref.                  | <0.0001 |
|                            | Conventional model +GFT| 0.65 (0.63–0.66)              | 0.11    | Ref.                  | 0.0003  |
| Combined vascular events   | Conventional model     | 0.64 (0.62–0.66)              | 0.11    | Ref.                  | 0.0003  |
|                            | Conventional model +GFT| 0.65 (0.63–0.66)              | 0.11    | Ref.                  | 0.0003  |
| 1 year                     |                        |                               |         |                       |         |
| Stroke recurrence          | Conventional model     | 0.62 (0.60–0.64)              | 0.13    | Ref.                  | 0.0005  |
|                            | Conventional model +GFT| 0.63 (0.61–0.64)              | 0.11    | Ref.                  | 0.0003  |
| Ischemic stroke            | Conventional model     | 0.62 (0.60–0.64)              | 0.11    | Ref.                  | 0.0003  |
|                            | Conventional model +GFT| 0.63 (0.61–0.64)              | 0.11    | Ref.                  | 0.0012  |
| Combined vascular events   | Conventional model     | 0.62 (0.60–0.64)              | 0.18    | Ref.                  |         |
|                            | Conventional model +GFT| 0.63 (0.61–0.65)              | 0.10    | Ref.                  | 0.04–0.15 |

Note: Conventional model: added to factor-adjusted models, including age, sex, body mass index, smoking, NIHSS score at admission, medical history of stroke, hypertension, dyslipidemia, diabetes mellitus, cardiovascular diseases.

Abbreviations: CI, confidence interval; IDI, integrated discrimination improvement; NRI, net reclassification improvement.

Impact of residual confounders, such as the location and size of stroke lesions, partial drug use and drug dosage, on the results were not completely excluded. Furthermore, this study collected only baseline GGT measurements; nevertheless, as a biomarker that reflects metabolism, GGT levels could present a dynamic change characteristic. Thus, we cannot rule out the possibility that this change may influence the role of GGT in stroke recurrence to some extent. The effect of dynamic changes in GGT on stroke recurrence needs to be further verified.

Biomarkers for the diagnosis and prognosis of stroke have always been a focus in this field. Recent research suggests that gut microbiomes related to inflammation may serve as biomarkers and therapeutic targets for stroke.48,49 After an injury caused by stroke occurs, DAMPs and cytokines are released from the brain, and the brain-gut axis involved in maintaining homeostasis is activated, causing intestinal inflammation and changes in immune activity and leading to intestinal barrier damage. Dysfunction of the intestinal immune system allows proinflammatory immune T cells to migrate from the gastrointestinal tract to the brain toward the site of injury, activating proinflammatory cytokines and exacerbating neuronal cell death. In addition, the inflammatory response after stroke is associated with long-term functional outcomes. Lymphocyte subsets are dynamically changing in stroke patients, which can reflect the local inflammation of the central nervous system. It has been found that T lymphocytes can participate in innate and acquired immune responses and can infiltrate into the brain parenchyma to exert proinflammatory and anti-inflammatory effects and promote brain injury and functional recovery. Among lymphocyte subsets, the percentage of CD4+ Tregs was a more sensitive biomarker to predict the prognosis of stroke and influence treatment strategies, and it had independent predictive ability for admission, discharge and neurological function at 3 months.50 Further studies on the correlation between circulating immunoregulatory lymphocytes and stroke deserve more attention. Moreover, a recent study suggested that enlarged perivascular spaces represent lymphatic drainage dysfunction in the body and are considered a feature of brain disorders, including small vascular disease, cognitive impairment, and epilepsy.51 The asymmetric distribution of perivascular spaces may be a new imaging biomarker for the development of brain diseases such as post-stroke epilepsy, and more research is needed in the future. As a component of the blood-brain barrier tight junction protein, serum occludin is also considered one of the biomarkers to predict the prognosis of stroke. A previous study suggested that the elevation of serum occludin is important to judge the damage to the blood-brain barrier in ischemic stroke.52 Elevated serum occludin levels at baseline were associated with a higher risk of hemorrhage transformation regardless of whether patients received reperfusion therapy, and it might be an independent risk factor for early neurological deterioration in patients receiving endovascular thrombectomy. Furthermore, the application value of circulating microRNAs as biomarkers in the diagnosis and prognosis of ischemic and hemorrhagic stroke has also been hotly discussed.53 In general, there are abundant studies on the correlation between biomarkers and stroke. Further studies are still needed to select biomarkers that are valuable in predicting the prognosis of stroke.

5 | CONCLUSION

In conclusion, as a low-cost, measurable and accurate biomarker, GGT activity was positively associated with the risk of stroke adverse outcomes, namely, recurrence, ischemic stroke, and combined
vascular events. This suggests that for stroke patients with high-GGT levels, more effective medical and lifestyle interventions should be performed as early as possible. More studies are still needed to further investigate the pathophysiological mechanism of GGT activity in the stroke population.

**AUTHOR CONTRIBUTIONS**

SQL and AXW designed the study and drafted the manuscript. XT and YTZ analyzed the data. AXW and XM contributed to reviewing the statistical problems. SQL and YMZ interpreted the data. YMZ reviewed the manuscript. All authors approved the final version of the manuscript.

**ACKNOWLEDGEMENT**

This work was supported by National Key Technology Research and Development Program of China (grant number. 2018YFC2002300, 2018YFC2002302, 2020YFC2004102), National Natural Science Foundation of China (grant number. 81972144, 81870905, U20A20358). We thank the staff and participants of the China National Stroke Registry-3 (CNSR-3) for their contribution.

**CONFLICT OF INTEREST**

All authors have nothing to disclose.

**DATA AVAILABILITY STATEMENT**

The analysis data are owned by China National Clinical Research Center for Neurological Diseases (http://paper.ncrcnd.ttctrc.com/). Data are not available at present but upon reasonable request and with permission.

**ORCID**

Siqi Li https://orcid.org/0000-0001-9227-3222

Anxin Wang https://orcid.org/0000-0003-4351-2877

Yumei Zhang https://orcid.org/0000-0003-0916-5525

**REFERENCES**

1. Campbell BCV, Khatri P. Stroke. Lancet. 2020;396:129-142. doi:10.1016/S0140-6736(20)31179-X

2. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139:e56-e528. doi:10.1161/CIR.000000000000659

3. Collaborators GBDRoS, Feigin VL, Nguyen G, et al. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med. 2018;379:2429-2437. doi:10.1056/NEJMoa1804492

4. Arsava EM, Kim GM, Oliveira-Filho J, et al. Prediction of early recurrence after acute ischemic stroke. JAMA Neurol. 2016;73:396-401. doi:10.1001/jamaneurol.2015.4949

5. Wang YJ, Li ZX, Gu HQ, et al. China stroke statistics 2019: a report from the National Center for healthcare quality Management in Neurological Diseases, China National Clinical Research Center for neurological diseases, the Chinese Stroke Association, National Center for chronic and noncommunicable disease control and prevention, Chinese Center for Disease Control and Prevention and institute for global neuroscience and stroke collaborations. Stroke Vasc Neurol. 2020;5(3):211-239. doi:10.1136/jsvn-2020-000457

6. Flach C, Muruet W, Wolfe CDA, Bhalla A, Douiri A. Risk and secondary prevention of stroke recurrence: a Population-Base cohort study. Stroke. 2020;51:2435-2444. doi:10.1161/STROKEAHA.120.028992

7. Koenig G, Seneff S. Gamma-Glutamyltransferase: a predictive biomarker of cellular antioxidant inadequacy and disease risk. Dis Markers. 2015;818570:2435-2444. doi:10.1161/STROKEAHA.120.028992

8. Ndreppega G, Kastriata A. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med. 2016;4:481. doi:10.21037/atm.2016.12.27

9. Akgul O, Uyarel H. G-glutamyl transferase: a novel prognostic marker for cardiovascular disease. J Crit Care. 2014;29:167-168. doi:10.1016/j.jcrc.2013.10.024

10. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38(4):263-355. doi:10.1016/S0362-4148(00)00041-8

11. Kunutsor SK. Gamma-glutamyltransferase-friend or foe within? Liver Int. 2016;36:1723-1734. doi:10.1111/liv.13221

12. Jeon J, Kim DH, Kim W, Choi DW, Jung KJ, Jang SL. Dose-response relationship between gamma-glutamyltransferase and the risk of atherosclerotic cardiovascular diseases in Korean adults. Atherosclerosis. 2020;292:152-159. doi:10.1016/j.atherosclerosis.2019.11.004

13. Wannamethee SG, Lennon L, Shaper AG. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis. 2008;201:168-175. doi:10.1016/j.atherosclerosis.2019.11.004

14. Zhang XW, Li M, Hou WS, Li K, Zhou JR, Tang YZ. Association between gamma-Glutamyltransferase level and risk of stroke: a systematic review and meta-analysis of prospective studies. J Stroke Cerebrovasc Dis. 2015;24:2816-2823. doi:10.1016/j.jstrokecerebrovasdis.2015.08.015

15. Nam KW, Kwon HM, Jeong HY, Park JH, Kim SH, Jeong SM. Serum gamma-glutamyl transferase is associated with silent brain infarcts in a healthy population. Atherosclerosis. 2019;280:45-50. doi:10.1016/j.atherosclerosis.2018.11.005

16. Yang W, Kim CK, Kim DY, Jeong HG, Lee SH. Gamma-glutamyl transferase predicts future stroke: a Korean nationwide study. Ann Neurol. 2018;83:375-386. doi:10.1002/ana.25158

17. Ruttmann E, Brant LJ, Concín H, et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation. 2005;112:2130-2137. doi:10.1161/CIRCULATIONAHA.105.552547

18. Chung HS, Lee JS, Kim JA, et al. Gamma-Glutamyltransferase variability and the risk of mortality, myocardial infarction, and stroke: a Nationwide population-based cohort study. J Clin Med. 2019;8(6):832. doi:10.3390/jcm8060832

19. Yang W, Kang DW, Lee SH. Effects of gamma-glutamyl transferase on stroke occurrence mediated by atrial fibrillation. J Clin Neurol. 2020;16(1):60-65. doi:10.3988/jcn.2020.16.1.60

20. Tu WJ, Liu Q, Cao JL, Zhao SJ, Zeng XW, Deng AJ. Gamma-glutamyl transferase as a risk factor for all-cause or cardiovascular disease mortality among 5912 ischemic stroke. Stroke. 2017;48:2888-2891. doi:10.1161/STROKEAHA.117.017776

21. Emdin M, Pissano C, Donato L, Paolicchi A, Pompella A. Serum gamma-glutamyl transferase as a risk factor of ischemic stroke might be independent of alcohol consumption. Stroke. 2002;33:1163-1164. doi:10.1161/01.STR.0100001234.35312.13

22. Yao T, Li J, Long Q, et al. Association between serum gamma-glutamyl transferase and intracranial arterial calcification in acute ischemic stroke subjects. Sci Rep. 2019;9:19998. doi:10.1038/s41598-019-56569-7

23. Weikert C, Drogan D, di Giuseppe R, et al. Liver enzymes and stroke risk in middle-aged German adults. Atherosclerosis. 2013;228(2):508-514. doi:10.1016/j.atherosclerosis.2013.03.026
24. Wang Y, Jing J, Meng X, et al. The third China National Stroke Registry (CNSR-III) for patients with acute ischemic stroke or transient ischemic attack: design, rationale and baseline patient characteristics. Stroke. 2019;4:158-164. doi:10.1136/svn-2019-000242

25. Hurford R, Li L, Lovett N, et al. Prognostic value of “tissue-based” definitions of TIA and minor stroke: population-based study. Neurology. 2019;92:e2455-e2461. doi:10.1212/WNL.0000000000007531

26. Stroke, W. H. O. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO task force on stroke and other cerebrovascular disorders. Stroke. 1989;20:1407-1431. doi:10.1161/01.STR.20.10.1407

27. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24:35-41. doi:10.1161/01.STR.24.1.35

28. Ruban A, Daya N, Schneider ALC, et al. Liver enzymes and risk of stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2020;20:357-368. doi:10.5833/jos.2020.00290

29. Shimizu Y, Imano H, Ohira T, et al. Gamma-Glutamyltransferase and incident stroke among Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Stroke. 2010;41:385-388. doi:10.1161/STROKEAHA.109.569061

30. Hong SH, Lee JS, Kim JA, et al. Gamma-glutamyl transferase variability and the risk of hospitalisation for heart failure. Heart. 2020;106:1080-1086. doi:10.1136/heartjnl-2019-316271

31. Yi SW, Lee SH, Hwang HJ, Yi JJ. Gamma-glutamyltransferase and cardiovascular mortality in Korean adults: a cohort study. Atherosclerosis. 2017;265:102-109. doi:10.1016/j.atherosclerosis.2017.08.028

32. Higashiya A, Wakabayashi I, Ono Y, et al. Association with serum gamma-glutamyltransferase levels and alcohol consumption on stroke and coronary artery disease: the Suita study. Stroke. 2011;42:1764-1767. doi:10.1161/STROKEAHA.110.608307

33. Fornaciari I, Fierabracci V, Corti A, et al. Gamma-glutamyltransferase fractions in human plasma and bile: characteristic and biogenesis. PLoS One. 2014;12(9):e88532. doi:10.1371/journal.pone.0088532

34. Emdin M, Pompella A, Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation. 2005;112:2078-2080. doi:10.1161/CIRCULATIONAHA.105.571919

35. Lee YJ, Kim JK, Lee JH, Lee HR, Kang DR, Shim JY. Association of serum gamma-glutamyltransferase with C-reactive protein levels and white blood cell count in Korean adults. Clin Chem Lab Med. 2008;46(10):1410-1415. doi:10.1515/CCLM.2008.280

36. Rodrigo R, Fernández-Gajardo R, Gutiérrez R, et al. Oxidative stress and pathophysiology of ischemic stroke: novel therapeutic opportunities. CNS Neural Disord Drug Targets. 2013;12(5):698-714. doi:10.2174/187152731312050015

37. Ren JX, Li C, Yan XL, Qu Y, Yang Y, Guo ZN. Crossover talk between oxidative stress and ferroptosis/Oxytosis in ischemic stroke: possible targets and molecular mechanisms. Oxid Med Cell Longev. 2021;2021:6643382. doi:10.1155/2021/6643382

38. Manolescu BN, Berteau M, Oprea E, et al. Dynamic of oxidative and nitrosative stress markers during the convalescent period of stroke patients undergoing rehabilitation. Ann Clin Biochem. 2011;48:338-343. doi:10.1258/acb.2011.010243

39. Gurbuzer N, Gokze E, Ayhan BZ. Gamma-glutamyl transferase levels in patients with acute ischemic stroke. Cardiovasc Psychiatry Neurol. 2014;2014:170626. doi:10.1155/2014/170626

40. Paolicchi A, Emdin M, Passino C, et al. Beta-lipoprotein- and LDL-associated serum gamma-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis. 2006;186(1):80-85. doi:10.1016/j.atherosclerosis.2005.07.012

41. Paolicchi A, Emdin M, Ghiozeni E, et al. Images in cardiovascular medicine. Human atherosclerotic plaques contain gamma-glutamyl transferase enzyme activity. Circulation. 2004;109(11):1440. doi:10.1161/CIRCULATIONAHA.104.391586.6

42. Pucci A, Franzini M, Matteucci M, et al. B-gamma-glutamyltransferase activity human vulnerable carotid plaques. Atherosclerosis. 2014;237:307-313. doi:10.1016/j.atherosclerosis.2014.09.028

43. Ndreppea G, Collera R, Kastrati A. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. Clin Chim Acta. 2018;476:130-138. doi:10.1016/j.cca.2017.11.026

44. Cho YK, Kang YM, Hwang JY, et al. Association between serum gamma-glutamyltransferase and the progression of coronary artery calcification. Atherosclerosis. 2015;243:300-306. doi:10.1016/j.atherosclerosis.2015.09.027

45. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women’s heart and health study and meta-analysis. Arterioscler Thromb Vasc Biol. 2007;27:2729-2735. doi:10.1161/ATVBAHA.107.152298

46. Ndreppea G, Xhepa E, Collera R, et al. Gamma-glutamyltransferase and atrial fibrillation in patients with coronary artery disease. Circ Arrhythm Electrophysiol. 2017;465:17-21. doi:10.1161/CIR.0000000000001200

47. Kunutsor SK, Laukkanen JA, Bluemke DA, Butler J, Khan H. Baseline and long-term gamma-glutamyltransferase, heart failure and cardiac arrhythmias in middle-aged Finnish men: prospective study and pooled analysis of published evidence. Eur J Prev Cardiol. 2016;23:1354-1362. doi:10.1177/2047487316644086

48. Kingsbury C, Shear A, Heyck M, et al. Inflammation-relevant microbiome signature of the stroke brain, gut, spleen, and thymus and the impact of exercise. J Cereb Blood Flow Metab. 2021;41(12):3200-3212. doi:10.1177/0271678X211039598

49. Cho J, Park YJ, Gonzales-Portillo B, et al. Gut dysbiosis in stroke and its implications on Alzheimer’s disease-like cognitive dysfunction. CNS Neurosci Ther. 2021;27(5):505-514. doi:10.1111/cns.13613

50. Li S, Huang Y, Liu Y, et al. Change and predictive ability of circulating miRNA expression & its implications on Alzheimer’s disease- like cognitive dysfunction. CNS Neurosci Ther. 2021;27(5):505-514. doi:10.1111/cns.13613

51. Fullerton JL, Thomas JM, Gonzalez-Trueba L, et al. Systematic review: association between circulating microRNA expression & stroke. J Cereb Blood Flow Metab. 2022;42(6):935-951. doi:10.1177/0271678X221085090

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.